	US 12,102,652 B2
	Constitutively active cytokine receptors for cell therapy
Thomas C. T. Shum, Houston, TX (US); Stephen M. G. Gottschalk, Houston, TX (US); Bilal Omer, Houston, TX (US); and Cliona M. Rooney, Bellaire, TX (US)
Assigned to Baylor College of Medicine, Houston, TX (US)
Appl. No. 16/326,270
Filed by Baylor College of Medicine, Houston, TX (US)
PCT Filed Aug. 11, 2017, PCT No. PCT/US2017/046588 § 371(c)(1), (2) Date Feb. 18, 2019, PCT Pub. No. WO2018/038945, PCT Pub. Date Mar. 1, 2018.
Claims priority of provisional application 62/380,021, filed on Aug. 26, 2016.
Prior Publication US 2019/0183936 A1, Jun. 20, 2019
Int. Cl. C07K 14/715 (2006.01); A61K 35/12 (2015.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/00 (2006.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01); C12N 15/85 (2006.01); A61K 38/00 (2006.01)

CPC A61K 35/17 (2013.01) [A61K 35/12 (2013.01); A61K 39/001119 (2018.08); A61P 35/00 (2018.01); C07K 14/00 (2013.01); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C07K 14/715 (2013.01); C07K 14/7155 (2013.01); C12N 15/85 (2013.01); A61K 38/00 (2013.01)]

21 Claims

1. A polynucleotide that encodes an engineered constitutively active receptor polypeptide, said polypeptide comprising the following components:

a) an TL-7 cytokine receptor alpha chain endodomain;

b) a transmembrane domain comprises the sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24; and

c) one or more extracellular domains, wherein the extracellular domain is from PD-1, B7, CD30, HER2, EGFR, CD19, CD34, TGF-beta receptor, IL-4 receptor, IL-13 receptor alpha1 and alpha 2, IL-8 receptor, IL-10 receptor, LAG3, TIGIT, CTLA4, FAS, CD27, CD28, CD52, CD134, CD137, or NGFR.